VECIMA-NETWORKS
17.5.2023 14:16:25 CEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) will showcase industry leadership at ANGA COM 2023, with technology demonstrations and panel presentations highlighting 10G PON fiber access solutions, Remote PHY (R-PHY) and Remote MACPHY (R-MACPHY) solutions, and next-generation video solutions, including Open CDN and Dynamic Content.
Technologies to be on display
Named by Dell’Oro Group as the global market share leader for Remote Optical Line Terminals (OLTs), Vecima expands its fiber access portfolio with a flexible, compact, and powerful shelf-based platform that supports all predominantly deployed Passive Optical Network (PON) variants. The Entra® EXS1610 All-PON™ Shelf allows customers to selectively deploy Distributed Access Architecture (DAA) and fiber to the home in any market or hub deployment, allowing maximum flexibility to deploy Cable Access and Fiber Access solutions based on specific subscriber need.
The Entra® EN2112 R-PHY Access Node is a high-density, compact, two-port node that’s interoperable with third-party converged cable access platform (CCAP) cores and vCMTS (virtual cable modem termination systems), creating an open, flexible DAA ecosystem. Supporting architectures that push fiber deeper into the network, the EN2112 allows operators to optimize existing hybrid fiber-coax (HFC) network capacity and deliver increased bandwidth to subscribers. Vecima recently announced that Kbro, Taiwan’s largest cable operator, selected the EN2112 R-PHY Node as part of its DAA solution to enable high-speed DOCSIS® 3.1 services for its subscribers.
The Entra® ERM3 Remote PHY Device (RPD) is designed to easily upgrade existing HFC nodes to DAA, reduce installation time, and lower operating costs for service providers while dramatically increasing broadband capacity. The ERM3 RPD boasts a unique form factor and features, highlighting Vecima’s open and interoperable approach to hardware and software. Like all RPDs in Vecima’s lineup, the ERM3 is interoperable with vCMTS and third-party CCAP cores. Vecima recently announced Charter Communications selected the ERM3 to enable 10G services over HFC networks.
The Entra® SC-1D Entra Access Node offers a Remote MACPHY/R-MACPHY Device in a compact, European form factor. Part of Vecima’s DAA solution that’s deployed in Europe, the SC-1D enables operators to deploy gigabit broadband and new services to residential subscribers and businesses. In addition, moving to DAA delivers sustainability through digitization, enabling substantial energy savings. Dell’Oro Group recently named Vecima as the global revenue share leader in Remote MACPHY devices.
Vecima’s MediaScale™ Streaming solutions, including Open CDN for high-quality, congestion-free streaming that’s more cost-effective and efficient, and Dynamic Content with Ad Insertion for highly targeted ads and more value per impression.
MediaScale Open CDN can be provisioned via Open Caching APIs to deliver and cache video content on behalf of the provisioning upstream provider’s content delivery network. It helps service providers monetize the terabytes of internet traffic delivered free of charge today and prepare their networks for the petabytes of content yet to come. The subscriber gets an improved viewing experience, without the headache of rebuffering and poor video quality.
Service providers can gain control over content with the MediaScale Dynamic Content solution which supports content rights, blackouts, and advertising. By manipulating content at the edge of the network, operators can deliver more efficient, personalized video content and more opportunities to monetize that content with targeted, higher-value ads.
Vecima speakers at ANGA COM
Vecima’s Chris Busch, Principal Architect Office of CTO, will speak on “Fiber Access and Measuring QoE – Taking a Slice of the Access Network” on Wednesday, May 24.
Quotes from Vecima executives attending ANGA COM
“Operators in the region need flexibility as they expand their networks and plan for future services, and Vecima’s portfolio provides multiple options to get to 10G,” said John Ruwe, Vice President of EMEA Sales at Vecima. “Vecima continues to increase our footprint in the European market, and we look forward to showcasing our technology leadership at ANGA COM.”
“Vecima is helping operators around the world evolve their networks with 10G-capable fiber and cable access solutions that prime them for future growth,” said Clay McCreery, Chief Operating Officer at Vecima. “We’re leading the way in delivering limitless broadband connectivity and content-rich video experiences across Europe and around the world.”
Visit Vecima Networks at ANGA COM 2023
May 23-25 in Cologne, Germany
Koelnmesse Hall 8, Stand D40
To schedule a meeting with the Vecima team, contact us at sales@vecima.com.
Media and industry analysts, please contact bernadette.dunn@vecima.com.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multigigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom